ANI Pharmaceuticals (NASDAQ:ANIP) Announces Earnings Results, Misses Expectations By $0.21 EPS

ANI Pharmaceuticals (NASDAQ:ANIPGet Rating) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.21), MarketWatch Earnings reports. ANI Pharmaceuticals had a positive return on equity of 14.10% and a negative net margin of 19.71%. During the same period in the prior year, the company earned $0.92 earnings per share. ANI Pharmaceuticals updated its FY 2022 guidance to $1.34-$1.62 EPS.

Shares of ANIP stock traded up $0.65 on Wednesday, hitting $25.93. The stock had a trading volume of 2,229 shares, compared to its average volume of 126,196. The company has a quick ratio of 2.74, a current ratio of 3.68 and a debt-to-equity ratio of 0.86. The business has a 50 day moving average price of $30.50 and a 200 day moving average price of $38.61. The company has a market cap of $447.86 million, a PE ratio of -7.80 and a beta of 1.06. ANI Pharmaceuticals has a one year low of $22.73 and a one year high of $60.23.

In related news, CEO Nikhil Lalwani bought 7,224 shares of the business’s stock in a transaction on Monday, March 21st. The shares were bought at an average price of $27.69 per share, for a total transaction of $200,032.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Patrick D. Walsh bought 5,000 shares of the business’s stock in a transaction on Monday, March 21st. The stock was bought at an average price of $27.76 per share, for a total transaction of $138,800.00. The disclosure for this purchase can be found here. Insiders purchased 17,224 shares of company stock valued at $477,083 over the last 90 days. 27.20% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in ANI Pharmaceuticals by 11.6% in the fourth quarter. BlackRock Inc. now owns 1,686,613 shares of the specialty pharmaceutical company’s stock valued at $77,721,000 after acquiring an additional 174,984 shares during the period. William Blair Investment Management LLC increased its position in shares of ANI Pharmaceuticals by 20.7% during the fourth quarter. William Blair Investment Management LLC now owns 451,444 shares of the specialty pharmaceutical company’s stock worth $20,803,000 after purchasing an additional 77,338 shares in the last quarter. State Street Corp increased its position in shares of ANI Pharmaceuticals by 6.5% during the fourth quarter. State Street Corp now owns 437,580 shares of the specialty pharmaceutical company’s stock worth $20,164,000 after purchasing an additional 26,560 shares in the last quarter. Deutsche Bank AG increased its position in shares of ANI Pharmaceuticals by 17.8% during the fourth quarter. Deutsche Bank AG now owns 226,640 shares of the specialty pharmaceutical company’s stock worth $10,443,000 after purchasing an additional 34,166 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of ANI Pharmaceuticals by 24.8% during the fourth quarter. Geode Capital Management LLC now owns 203,453 shares of the specialty pharmaceutical company’s stock worth $9,375,000 after purchasing an additional 40,416 shares in the last quarter. Hedge funds and other institutional investors own 59.66% of the company’s stock.

Several analysts have recently weighed in on the company. Raymond James decreased their target price on ANI Pharmaceuticals from $65.00 to $47.00 and set an “outperform” rating for the company in a research report on Wednesday, March 16th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ANI Pharmaceuticals in a research report on Wednesday, March 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 14th. TheStreet downgraded ANI Pharmaceuticals from a “c-” rating to a “d+” rating in a research report on Wednesday, March 30th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $56.67.

About ANI Pharmaceuticals (Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.

Recommended Stories

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.